Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
63
GPCR Quote, Financials, Valuation and Earnings
Last price:
$69.61
Seasonality move
:
-34.19%
Day range:
$63.21 - $71.75
52-week range:
$13.22 - $94.90
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
5.33x
Volume:
2.1M
Avg. volume:
2.2M
1-year change:
149.44%
Market cap:
$4.1B
Revenue:
--
EPS (TTM):
-$3.65
Analysts' Opinion
-
Consensus RatingStructure Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 10 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $99.43, Structure Therapeutics, Inc. has an estimated upside of 39.47% from its current price of $71.29.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $65.00 representing 100% downside risk from its current price of $71.29.
Fair Value
-
According to the consensus of 10 analysts, Structure Therapeutics, Inc. has 39.47% upside to fair value with a price target of $99.43 per share.
GPCR vs. S&P 500
-
Over the past 5 trading days, Structure Therapeutics, Inc. has overperformed the S&P 500 by 13.27% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Structure Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Structure Therapeutics, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Structure Therapeutics, Inc. reported revenues of --.
Earnings Growth
-
Structure Therapeutics, Inc. earnings have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Structure Therapeutics, Inc. reported earnings per share of -$1.13.
Enterprise value:
3.3B
EV / Invested capital:
4.26x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-0.30x
EV / Free cash flow:
-16.85x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$4.4M
Return On Assets:
-24.24%
Net Income Margin (TTM):
--
Return On Equity:
-25.55%
Return On Invested Capital:
-25.36%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$812.7K | -$1.4M | -$4.4M | -$267.2K | -$978.3K | |
| Operating Income | -$84.4M | -$142.7M | -$247.9M | -$46.2M | -$73.9M | |
| EBITDA | -$83.6M | -$141.2M | -$243.5M | -$45.9M | -$72.9M | |
| Diluted EPS | -$2.30 | -$2.21 | -$3.65 | -$0.60 | -$1.13 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | $210M | $923.7M | $814M | |
| Total Assets | -- | -- | $216.4M | $933.2M | $832.2M | |
| Current Liabilities | -- | -- | $20.1M | $33.4M | $57.5M | |
| Total Liabilities | -- | -- | $23.4M | $36.4M | $62.1M | |
| Total Equity | -- | -- | $193M | $896.8M | $770M | |
| Total Debt | -- | -- | $3M | $2.7M | $4.3M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$69.8M | -$102.2M | -$194.5M | -$19.9M | -$51M | |
| Cash From Investing | -$77.3M | -$573.5M | $67.2M | -$189.8M | -$49.5M | |
| Cash From Financing | $169.6M | $797.2M | $57.9M | $512.9K | $56.3M | |
| Free Cash Flow | -$70.9M | -$104.6M | -$196.7M | -$20.6M | -$52.6M | |
GPCR
Sector
Market Cap
$4.1B
$28.1M
Price % of 52-Week High
75.12%
51.39%
Dividend Yield
0%
0%
Shareholder Yield
-3.66%
-1.49%
1-Year Price Total Return
149.44%
-17.13%
Beta (5-Year)
--
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$64.43
200-day SMA
Buy
Level
$26.09
Bollinger Bands (100)
Buy
Level
17 - 45.24
Chaikin Money Flow
Sell
Level
-37.3M
20-day SMA
Buy
Level
$52.92
Relative Strength Index (RSI14)
Buy
Level
72.85
ADX Line
Buy
Level
51.1
Williams %R
Neutral
Level
-36.9137
50-day SMA
Buy
Level
$40.28
MACD (12, 26)
Buy
Level
8.50
25-day Aroon Oscillator
Buy
Level
8
On Balance Volume
Neutral
Level
38.9M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (24.2681)
Buy
CA Score
(Annual)
Level (0.5756)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (2.5648)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its pipeline includes Aleniglipron GSBR-1290, ACCG-2671, GIPR, GCGR, ANPA-0073, and LTSE-2578. The company was founded by Raymond C. Stevens in 2016 and is headquartered in South San Francisco, CA.
Stock Forecast FAQ
In the current month, GPCR has received 10 Buy ratings 0 Hold ratings, and 0 Sell ratings. The GPCR average analyst price target in the past 3 months is $99.43.
-
Where Will Structure Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Structure Therapeutics, Inc. share price will rise to $99.43 per share over the next 12 months.
-
What Do Analysts Say About Structure Therapeutics, Inc.?
Analysts are divided on their view about Structure Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Structure Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $65.00.
-
What Is Structure Therapeutics, Inc.'s Price Target?
The price target for Structure Therapeutics, Inc. over the next 1-year time period is forecast to be $99.43 according to 10 Wall Street analysts, 10 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is GPCR A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Structure Therapeutics, Inc. is a Buy. 10 of 10 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of GPCR?
You can purchase shares of Structure Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Structure Therapeutics, Inc. shares.
-
What Is The Structure Therapeutics, Inc. Share Price Today?
Structure Therapeutics, Inc. was last trading at $69.61 per share. This represents the most recent stock quote for Structure Therapeutics, Inc.. Yesterday, Structure Therapeutics, Inc. closed at $71.29 per share.
-
How To Buy Structure Therapeutics, Inc. Stock Online?
In order to purchase Structure Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get GPCR Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
GPCR
Sector
P/E ratio
--
23.89x
PEG ratio
-0.30x
-0.01x
P/B ratio
5.33x
1.81x
Price / LTM sales
--
1.59x
Growth Metrics
GPCR
Sector
Revenue growth
--
4.62%
Earnings growth
-87.88%
11.06%
Revenue (5-year growth)
--
6.5%
Earnings forecast
-$0.43
-$0.21
Profitability
GPCR
Sector
Profitability FY 2024
-$2.6M
$3.6M
Return on invested capital
-25.36%
-31.84%
Return on assets
-24.24%
-27.96%
Return on equity
-25.55%
-37.63%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Feb
26
Estimated Next Earnings Date
Feb
5
Balance Sheet
GPCR
Sector
Total cash
$799M
$26.4M
Short term investments
$714M
$25.7M
Total assets
$903.3M
$76.9M
Long term debt
$4.3M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
85
HUT alert for Dec 24
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Buy
63
GPCR alert for Dec 24
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.
Sell
32
SMX alert for Dec 24
SMX (Security Matters) Plc [SMX] is down 8.94% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
